कंपनी का अवलोकन
Veru Inc. operates as a late clinical stage biopharmaceutical entity headquartered in Florida, dedicated to the development of therapeutic medicines for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS), while also offering FC2 female condoms for dual protection. The company functions within the broader healthcare sector, specifically categorized under the biotechnology industry, which implies a focus on innovation-driven research and development with significant regulatory hurdles and long timelines to commercialization. Currently, the firm maintains a market capitalization of $40.93M and employs a workforce of 20 individuals, indicating a small-cap structure typical of early-to-mid stage biotech firms. The market cap figure of $40.93M, combined with the absence of reported annual revenue figures in the available data, suggests that the company's valuation is derived primarily from its clinical pipeline and potential future cash flows rather than established commercial earnings, reflecting a high-risk, high-potential position in the biotechnology landscape.
वित्तीय स्वास्थ्य
Veru Inc. reports a net income of $-19,203,932 and an EBITDA of $-29,895,576 over the trailing twelve months, while specific revenue and price-to-sales metrics are not available for the trailing twelve months period. The substantial gap between the reported net income loss of $-19,203,932 and the even deeper EBITDA loss of $-29,895,576 reveals a cost structure heavily weighted towards research, development, and operational expenses that are not yet offset by commercial revenue generation. The company's free cash flow stands at $-11,035,380, which indicates a significant cash burn rate and limited financial flexibility, requiring continuous capital raising or existing cash reserves to sustain operations. Analysis of the three available margin metrics shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which indicate that the company is currently unable to generate positive profitability from its sales or operations, a common characteristic in the pre-revenue biotechnology sector. In terms of balance sheet strength, Veru Inc. holds $35.30M in cash against $2.98M in debt, resulting in a debt-to-equity ratio of 8.02, which suggests a leveraged capital structure where equity is relatively small compared to total debt obligations. Despite the debt level, the current ratio is reported at 5.16, indicating a strong position in short-term liquidity relative to immediate obligations, providing a buffer for operational continuity. Furthermore, the return on equity is -60.2% and the return on assets is -42.9%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, reflecting the high investment phase of the business model.
मूल्यांकन आकलन
The valuation metrics for Veru Inc. include a P/E ratio (TTM) listed as N/A and a forward P/E of -2.12, where the negative forward P/E implies that the market expects earnings to remain negative in the coming period or that current earnings are so low they invert the standard ratio calculation. The price-to-book ratio is recorded at 1.10, suggesting that the market values the company at a level slightly above its book value, which is often the case for asset-light biotechnology companies where intangible value like intellectual property is not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -0.29, provide additional context, with the negative EV/EBITDA reinforcing the expectation of future profitability rather than current earnings power. The stock has traded within a 52-week range with a high of $7.40 and a low of $2.06, and without a specific current price provided in the facts, the valuation is strictly defined by these historical extremes which bound the potential trading range. The beta value is -1.34, a highly unusual negative figure that technically implies an inverse correlation to the broader market, meaning the stock theoretically moves in the opposite direction of the market index, though such behavior is atypical and warrants careful interpretation of volatility relative to the broader market.
Growth & Income
The available data indicates that revenue growth year-over-year and earnings growth year-over-year are both N/A, meaning there are no quantified historical growth rates to compare earnings expansion against revenue expansion or to determine if earnings are growing faster or slower than revenue. As the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, which explains that the firm reinvests all available earnings, or in this case, utilizes its cash reserves, into growth initiatives such as clinical trials and drug development rather than paying out returns to shareholders. Consequently, the overall growth and income profile for Veru Inc. is characterized by zero dividend income and undefined historical growth rates, positioning the company as a pure growth play dependent on future commercial success rather than current income generation or dividend stability.